Risk Factors Update Summary

• Change from $20 million to $0 million aggregate principal amount in the Avenue Loan Agreement.
• Change from $11 million to $12.7 million in cash and cash equivalents as of December 31, 2022.
• Compliance costs may increase net loss, impacting attractiveness to investors with common stock.
• HEPZATO now approved for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.
• Change from $19.8 million to $0 million in short-term investments as of December 31, 2022.
• Change from $15 million to $0 million borrowed as of the date hereof.
• Change from $36.5 million to $47.7 million in net losses for the year ended December 31, 2022.
• Addition of experiencing a security incident from third parties may lead to data breaches.
• FDA approval for a product candidate may result in marketable products and system approval.
• Increased legal expenses even if prevailing on merits due to claims against the company.
• Change from $25.6 million to $36.5 million in net losses for the year ended December 31, 2021.
• Potential changes in healthcare laws could impact the demand for products like HEPTAZO.
• Change from 15% to 16% interest rate on the Avenue Loan Agreement as of December 31, 2023.
• Legislation may subject drug manufacturers to new annual fees and taxes, impacting financials.
• Failure to comply with information privacy and security laws may result in significant civil and criminal consequences.
• Increased focus on privacy and data protection laws may lead to compliance challenges and legal risks.
• Security incidents could lead to adverse consequences, including financial loss and reputational harm.